Kidswell Bio Corporation

As of March 31, 2026, Kidswell Bio Corporation carries a market capitalization of 12.06B, placing it among publicly traded companies globally. Its enterprise value stands at 11.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kidswell Bio Corporation's next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, Kidswell Bio Corporation has 49.62M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Kidswell Bio Corporation maintains a current ratio of 2.72, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Kidswell Bio Corporation's stock has declined approximately 41.76% over the past 52 weeks. The 50-day moving average sits at 163.86, while the 200-day moving average is 198.12.

As of March 31, 2026, Kidswell Bio Corporation holds 3.29B in cash and equivalents against 2.55B in total debt, resulting in a net debt position of -744.92M. Total book value stands at 1.65B, with working capital of 3.69B providing operational flexibility.

Kidswell Bio Corporation's most recent stock split took place on June 27, 2018 with a 1:2 split ratio.